Literature DB >> 28062724

MTHFR C677T polymorphism is associated with methotrexate-induced myelopathy risk.

Kelsey Juster-Switlyk1, A Gordon Smith1, Tibor Kovacsovics1, Deborah Stephens1, Martha Glenn1, Cheryl Ann Palmer1, Edward P Quigley1, Noah Kolb2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28062724      PMCID： PMC5304461          DOI： 10.1212/WNL.0000000000003590

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

1.  C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease.

Authors:  N Q Hanson; O Aras ; F Yang; M Y Tsai
Journal:  Clin Chem       Date:  2001-04       Impact factor: 8.327

Review 2.  Potential outcome factors in subacute combined degeneration: review of observational studies.

Authors:  Olavo M Vasconcelos; Erika H Poehm; Robert J McCarter; William W Campbell; Zenaide M N Quezado
Journal:  J Gen Intern Med       Date:  2006-10       Impact factor: 5.128

3.  Myelopathy following intrathecal chemotherapy in adults: a single institution experience.

Authors:  David Cachia; Carlos Kamiya-Matsuoka; Chelsea C Pinnix; Linda Chi; Hagop M Kantarjian; Jorge E Cortes; Naval Daver; Karin Woodman
Journal:  J Neurooncol       Date:  2015-02-10       Impact factor: 4.130

4.  Methotrexate myelopathy with extensive transverse necrosis: report of an autopsy case.

Authors:  Masayuki Shintaku; Nao Toyooka; Takashi Koyama; Shunsuke Teraoka; Mitsuru Tsudo
Journal:  Neuropathology       Date:  2014-07-02       Impact factor: 1.906

5.  Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism.

Authors:  C M Ulrich; Y Yasui; R Storb; M M Schubert; J L Wagner; J Bigler; K S Ariail; C L Keener; S Li; H Liu; F M Farin; J D Potter
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

6.  Methotrexate-induced myelopathy responsive to substitution of multiple folate metabolites.

Authors:  R Ackermann; A Semmler; G D Maurer; E Hattingen; F Fornoff; J P Steinbach; M Linnebank
Journal:  J Neurooncol       Date:  2009-10-11       Impact factor: 4.130
  6 in total
  2 in total

1.  Rapidly ascending necrotizing myelopathy with widespread brain white matter involvement following intrathecal methotrexate and cytosine arabinoside treatment in an adult with T cell acute lymphoblastic leukemia.

Authors:  C Lapucci; E Capello; N Romano; F Guolo; N Mavilio; L Roccatagliata
Journal:  Neurol Sci       Date:  2018-05-04       Impact factor: 3.307

2.  Intrathecal cytosine arabinoside-induced progression of chronic methotrexate myelopathy.

Authors:  L Mikhelashvili; A Haboosheh; V Vainstein; A Lossos
Journal:  Neurol Sci       Date:  2020-08-11       Impact factor: 3.307
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.